BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582-90. [PMID: 17582068 DOI: 10.1056/NEJMoa070389] [Cited by in Crossref: 516] [Cited by in F6Publishing: 220] [Article Influence: 36.9] [Reference Citation Analysis]
Number Citing Articles
1 Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F. How we manage smoldering multiple myeloma. Hematol Rep 2020;12:8951. [PMID: 33042502 DOI: 10.4081/hr.2020.8951] [Reference Citation Analysis]
2 Bhutani M, Landgren O. [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future]. Radiologe 2014;54:572, 574-81. [PMID: 24927659 DOI: 10.1007/s00117-014-2694-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
3 Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin 2016;6:12-8. [PMID: 27331023 DOI: 10.1016/j.bbacli.2016.05.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
4 Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9:278-88. [PMID: 19717377 DOI: 10.3816/CLM.2009.n.056] [Cited by in Crossref: 106] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
5 Blum A, Bazou D, O'Gorman P. Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions. Blood Lymphat Cancer 2018;8:21-31. [PMID: 31360091 DOI: 10.2147/BLCTT.S136447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Sundararajan S, Kumar A, Korde N, Agarwal A. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics. Curr Hematol Malig Rep 2016;11:102-10. [PMID: 26894382 DOI: 10.1007/s11899-016-0305-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A, Morice WG, Rajkumar SV. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013;27:680-5. [PMID: 22902364 DOI: 10.1038/leu.2012.237] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 11.0] [Reference Citation Analysis]
8 Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia 2019;33:1273-7. [PMID: 30787429 DOI: 10.1038/s41375-019-0419-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 Gonsalves WI, Ramakrishnan V, Hitosugi T, Ghosh T, Jevremovic D, Dutta T, Sakrikar D, Petterson XM, Wellik L, Kumar SK, Nair KS. Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. JCI Insight 2018;3:94543. [PMID: 29321378 DOI: 10.1172/jci.insight.94543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
10 Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 2016;128:2599-606. [PMID: 27737890 DOI: 10.1182/blood-2016-09-692954] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 14.0] [Reference Citation Analysis]
11 Sanoja-Flores L, Flores-Montero J, Pérez-Andrés M, Puig N, Orfao A. Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications. Cancers (Basel) 2020;12:E1499. [PMID: 32521788 DOI: 10.3390/cancers12061499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Zhou X, Dierks A, Kertels O, Kircher M, Schirbel A, Samnick S, Buck AK, Knorz S, Böckle D, Scheller L, Messerschmidt J, Barakat M, Kortüm KM, Rasche L, Einsele H, Lapa C. 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features. Cancers (Basel) 2020;12:E2333. [PMID: 32824832 DOI: 10.3390/cancers12082333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, Kyle RA, Berenson JR, Dispenzieri A. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J 2021;11:120. [PMID: 34168119 DOI: 10.1038/s41408-021-00505-4] [Reference Citation Analysis]
14 Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 2018;8:59. [PMID: 29895887 DOI: 10.1038/s41408-018-0077-4] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 28.3] [Reference Citation Analysis]
15 Waxman AJ, Kuehl M, Balakumaran A, Weiss B, Landgren O. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Clin Lymphoma Myeloma Leuk 2010;10:248-57. [PMID: 20709660 DOI: 10.3816/CLML.2010.n.053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
16 Bent R, Moll L, Grabbe S, Bros M. Interleukin-1 Beta-A Friend or Foe in Malignancies? Int J Mol Sci 2018;19:E2155. [PMID: 30042333 DOI: 10.3390/ijms19082155] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 29.0] [Reference Citation Analysis]
17 Späth F, Wibom C, Krop EJM, Santamaria AI, Johansson AS, Bergdahl IA, Hultdin J, Vermeulen R, Melin B. Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples. Haematologica 2019;104:2456-64. [PMID: 30948485 DOI: 10.3324/haematol.2019.216895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv 2018;2:3149-54. [PMID: 30463914 DOI: 10.1182/bloodadvances.2018024794] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
19 Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 2018;378:241-9. [PMID: 29342381 DOI: 10.1056/NEJMoa1709974] [Cited by in Crossref: 188] [Cited by in F6Publishing: 89] [Article Influence: 62.7] [Reference Citation Analysis]
20 Zhang L, Lei Q, Wang H, Xu C, Liu T, Kong F, Yang C, Yan G, Sun L, Zhao A, Chen W, Hu Y, Xie H, Cao Y, Fu F, Yuan G, Chen Z, Guo AY, Li Q. Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease. Theranostics 2019;9:196-209. [PMID: 30662562 DOI: 10.7150/thno.27550] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
21 Landgren O, Waxman AJ. Multiple myeloma precursor disease. JAMA 2010;304:2397-404. [PMID: 21119086 DOI: 10.1001/jama.2010.1713] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
22 Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor HU, Schlemmer HP, Delorme S, Goldschmidt H, Weinhold N, Hillengass J, Weber MA. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers (Basel) 2021;13:961. [PMID: 33668879 DOI: 10.3390/cancers13050961] [Reference Citation Analysis]
23 Dutta AK, Fink JL, Grady JP, Morgan GJ, Mullighan CG, To LB, Hewett DR, Zannettino ACW. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia 2019;33:457-68. [PMID: 30046162 DOI: 10.1038/s41375-018-0206-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 15.3] [Reference Citation Analysis]
24 Kristinsson SY, Björkholm M, Andersson TM, Eloranta S, Dickman PW, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 2009;94:1714-20. [PMID: 19608666 DOI: 10.3324/haematol.2009.010066] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
25 Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, Wäsch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist 2016;21:333-42. [PMID: 26921288 DOI: 10.1634/theoncologist.2015-0303] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
26 Spaan I, Raymakers RA, van de Stolpe A, Peperzak V. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. J Hematol Oncol 2018;11:67. [PMID: 29776381 DOI: 10.1186/s13045-018-0615-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
27 Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011;365:474-5. [PMID: 21812699 DOI: 10.1056/NEJMc1106428] [Cited by in Crossref: 127] [Cited by in F6Publishing: 36] [Article Influence: 12.7] [Reference Citation Analysis]
28 Painuly U, Kumar S. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol 2013;7:53-73. [PMID: 23492937 DOI: 10.4137/CMO.S7764] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
29 Kristinsson SY, Minter AR, Korde N, Tan E, Landgren O. Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn 2011;11:593-603. [PMID: 21745013 DOI: 10.1586/erm.11.44] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
30 Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, Garrido V, Rufian L, Sanchez R, Aguilar-Garrido P, Barrio S, Martín MA, Bolli N, Tai YT, Szalat R, Fulciniti M, Munshi N, Martínez-López J, Linares M, Gallardo M. Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers (Basel) 2021;13:3189. [PMID: 34202390 DOI: 10.3390/cancers13133189] [Reference Citation Analysis]
31 Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med 2011;269:16-28. [PMID: 21158974 DOI: 10.1111/j.1365-2796.2010.02313.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 9.3] [Reference Citation Analysis]
32 Hillengass J, Delorme S. [Multiple myeloma: current recommendations for imaging]. Radiologe 2012;52:360-5. [PMID: 22441560 DOI: 10.1007/s00117-011-2257-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
33 Gao M, Yang G, Kong Y, Wu X, Shi J. Smoldering multiple myeloma. Biomed Res Int 2015;2015:623254. [PMID: 26000300 DOI: 10.1155/2015/623254] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Schuster SR, Rajkumar SV, Dispenzieri A, Morice W, Aspitia AM, Ansell S, Kyle R, Mikhael J. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol 2010;85:853-5. [PMID: 20842638 DOI: 10.1002/ajh.21845] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
35 Maura F, Bolli N, Rustad EH, Hultcrantz M, Munshi N, Landgren O. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. JAMA Oncol 2020;6:425-32. [PMID: 31830214 DOI: 10.1001/jamaoncol.2019.4659] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
36 Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica 2015;100:1214-21. [PMID: 26022710 DOI: 10.3324/haematol.2015.124651] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
37 Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, Cerchione C. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments. Front Oncol 2020;10:624661. [PMID: 33680948 DOI: 10.3389/fonc.2020.624661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, Kumar S, Garbitt VM, Sharik ME, Henderson KJ, Tonon G, Tomura M, Miwa Y, Esplugues E, Flavell RA, Huber S, Canducci F, Rajkumar VS, Bergsagel PL, Bellone M. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun 2018;9:4832. [PMID: 30510245 DOI: 10.1038/s41467-018-07305-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 19.3] [Reference Citation Analysis]
39 Bosseboeuf A, Seillier C, Mennesson N, Allain-Maillet S, Fourny M, Tallet A, Piver E, Lehours P, Mégraud F, Berthelot L, Harb J, Bigot-Corbel E, Hermouet S. Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients. Front Immunol 2020;11:854. [PMID: 32536913 DOI: 10.3389/fimmu.2020.00854] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Singh G. Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio. J Clin Med Res 2017;9:46-57. [PMID: 27924175 DOI: 10.14740/jocmr2802w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
41 Maatouk I, He S, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Herzog W, Hillengass J. Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma. Blood Cancer J 2019;9:9. [PMID: 30664623 DOI: 10.1038/s41408-019-0172-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Díaz-Tejedor A, Lorenzo-Mohamed M, Puig N, García-Sanz R, Mateos MV, Garayoa M, Paíno T. Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers (Basel) 2021;13:1353. [PMID: 33802806 DOI: 10.3390/cancers13061353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
43 Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:78-88. [PMID: 22180161 DOI: 10.1002/ajh.22237] [Cited by in Crossref: 104] [Cited by in F6Publishing: 80] [Article Influence: 11.6] [Reference Citation Analysis]
44 Da Vià MC, Ziccheddu B, Maeda A, Bagnoli F, Perrone G, Bolli N. A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. Hemasphere 2020;4:e502. [PMID: 33283171 DOI: 10.1097/HS9.0000000000000502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
45 Rajkumar SV. Myeloma today: Disease definitions and treatment advances. Am J Hematol 2016;91:90-100. [PMID: 26565896 DOI: 10.1002/ajh.24236] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
46 Shah R, Shah N, Shah A, Mehta AN. Steroid-resistant nephrotic syndrome secondary to primary focal segmental glomerulosclerosis and smoldering multiple myeloma. Proc (Bayl Univ Med Cent) 2014;27:19-21. [PMID: 24381395 DOI: 10.1080/08998280.2014.11929039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Bolli N, Sgherza N, Curci P, Rizzi R, Strafella V, Delia M, Gagliardi VP, Neri A, Baldini L, Albano F, Musto P. What Is New in the Treatment of Smoldering Multiple Myeloma? J Clin Med 2021;10:421. [PMID: 33499196 DOI: 10.3390/jcm10030421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Princic N, Gregory C, Willson T, Mahue M, Felici D, Werther W, Lenhart G, Foley KA. Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data. Front Oncol 2016;6:224. [PMID: 27833899 DOI: 10.3389/fonc.2016.00224] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
49 Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, Emanuel M, Petrosyan A, Bhutani M, Calvo KR, Dulau-Florea A, Kwok M, Lee MJ, Lee S, Lindenberg L, Mailankody S, Manasanch E, Maric I, Mena E, Patel N, Tageja N, Trepel JB, Turkbey B, Wang HW, Wang W, Yuan C, Zhang Y, Braylan R, Choyke P, Stetler-Stevenson M, Steinberg SM, Figg WD Sr, Roschewski M, Landgren O. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol 2021. [PMID: 34529025 DOI: 10.1001/jamaoncol.2021.3971] [Reference Citation Analysis]
50 Li N, Johnson DC, Weinhold N, Kimber S, Dobbins SE, Mitchell JS, Kinnersley B, Sud A, Law PJ, Orlando G, Scales M, Wardell CP, Försti A, Hoang PH, Went M, Holroyd A, Hariri F, Pastinen T, Meissner T, Goldschmidt H, Hemminki K, Morgan GJ, Kaiser M, Houlston RS. Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. Cell Rep 2017;20:2556-64. [PMID: 28903037 DOI: 10.1016/j.celrep.2017.08.062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
51 Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood 2015;125:3069-75. [PMID: 25838344 DOI: 10.1182/blood-2014-09-568899] [Cited by in Crossref: 135] [Cited by in F6Publishing: 118] [Article Influence: 22.5] [Reference Citation Analysis]
52 Atrash S, Robinson M, Slaughter D, Aneralla A, Brown T, Robinson J, Ndiaye A, Sprouse C, Zhang Q, Symanowski JT, Friend R, Voorhees PM, Usmani SZ, Bhutani M. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood Cancer J 2018;8:107. [PMID: 30410066 DOI: 10.1038/s41408-018-0144-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
53 Hassan H, Szalat R. Genetic Predictors of Mortality in Patients with Multiple Myeloma. Appl Clin Genet 2021;14:241-54. [PMID: 33953598 DOI: 10.2147/TACG.S262866] [Reference Citation Analysis]
54 Landgren O. Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. Hematology Am Soc Hematol Educ Program 2010;2010:295-302. [PMID: 21239809 DOI: 10.1182/asheducation-2010.1.295] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
55 Feyereisn WL, Fenstad ER, McCully RB, Lacy MQ. Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature. Pulm Circ 2015;5:211-6. [PMID: 25992284 DOI: 10.1086/679726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
56 Zhao J, Wang M, He P, Chen Y, Wang X, Zhang M. Identification of glutathione S-transferase π 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling. Oncol Lett 2020;19:2153-62. [PMID: 32194713 DOI: 10.3892/ol.2020.11321] [Reference Citation Analysis]
57 Chhabra S, Jain S, Wallace C, Hong F, Liu B. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. J Hematol Oncol 2015;8:77. [PMID: 26108343 DOI: 10.1186/s13045-015-0177-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
58 Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013;54:2215-8. [PMID: 23311294 DOI: 10.3109/10428194.2013.764419] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
59 Ramakrishnan V, Mager DE. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells. J Pharmacol Exp Ther 2018;365:734-51. [PMID: 29632237 DOI: 10.1124/jpet.118.247924] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor HU, Schlemmer HP, Delorme S, Goldschmidt H, Weinhold N, Hillengass J, Weber MA. Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria. Cancers (Basel) 2020;12:E2537. [PMID: 32906608 DOI: 10.3390/cancers12092537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
61 Manzoni M, Pompa A, Fabris S, Pelizzoni F, Ciceri G, Seia M, Ziccheddu B, Bolli N, Corradini P, Baldini L, Neri A, Lionetti M. Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. Hemasphere 2020;4:e402. [PMID: 32903996 DOI: 10.1097/HS9.0000000000000402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
62 Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol 2010;85:737-40. [PMID: 20730790 DOI: 10.1002/ajh.21821] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
63 Girnius S, Munshi NC. Challenges in multiple myeloma diagnosis and treatment. Leuk Suppl 2013;2:S3-9. [PMID: 27175259 DOI: 10.1038/leusup.2013.2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
64 Zhang L, Liu D, Tang B, Xu A, Huang H, Su Y, Xu J, Deng J, Tang L, Sun C, Hu Y. MicroRNA-324-5p suppresses the migration and invasion of MM cells by inhibiting the SCFβ-TrCP E3 ligase. Oncol Lett 2018;16:5331-8. [PMID: 30250603 DOI: 10.3892/ol.2018.9245] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
65 Xu K, Hu X, Sun L, Liang Q, Ouyang G, Zhang Y, Mu Q, Yan X. MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1. Hum Cell 2019;32:529-39. [PMID: 31452083 DOI: 10.1007/s13577-019-00276-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Pawlyn C, Gay F, Larocca A, Roy V, Ailawadhi S. Nuances in the Management of Older People With Multiple Myeloma. Curr Hematol Malig Rep 2016;11:241-51. [PMID: 27038805 DOI: 10.1007/s11899-016-0323-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
67 Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Curr Hematol Malig Rep 2010;5:62-9. [PMID: 20425398 DOI: 10.1007/s11899-010-0047-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
68 Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol 2011;94:310-20. [PMID: 22005834 DOI: 10.1007/s12185-011-0947-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
69 Misso G, Zarone MR, Lombardi A, Grimaldi A, Cossu AM, Ferri C, Russo M, Vuoso DC, Luce A, Kawasaki H, Di Martino MT, Virgilio A, Festa A, Galeone A, De Rosa G, Irace C, Donadelli M, Necas A, Amler E, Tagliaferri P, Tassone P, Caraglia M. miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. Mol Ther Nucleic Acids 2019;16:391-406. [PMID: 31009917 DOI: 10.1016/j.omtn.2019.02.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
70 Saltarella I, Lamanuzzi A, Reale A, Vacca A, Ria R. Identify multiple myeloma stem cells: Utopia? World J Stem Cells 2015; 7(1): 84-95 [PMID: 25621108 DOI: 10.4252/wjsc.v7.i1.84] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
71 Wichert S, Juliusson G, Johansson Å, Sonesson E, Teige I, Wickenberg AT, Frendeus B, Korsgren M, Hansson M. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. PLoS One 2017;12:e0171205. [PMID: 28158311 DOI: 10.1371/journal.pone.0171205] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
72 Lee WS, Singh G. Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies. J Clin Med Res 2018;10:562-9. [PMID: 29904440 DOI: 10.14740/jocmr3383w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
73 Jones CI, Zabolotskaya MV, King AJ, Stewart HJ, Horne GA, Chevassut TJ, Newbury SF. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer 2012;107:1987-96. [PMID: 23169280 DOI: 10.1038/bjc.2012.525] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 11.2] [Reference Citation Analysis]
74 Jelinek T, Bezdekova R, Zatopkova M, Burgos L, Simicek M, Sevcikova T, Paiva B, Hajek R. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J 2017;7:e617. [PMID: 29053157 DOI: 10.1038/bcj.2017.90] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
75 Rajkumar SV, Kyle RA. Haematological cancer: Treatment of smoldering multiple myeloma. Nat Rev Clin Oncol 2013;10:554-5. [PMID: 23999214 DOI: 10.1038/nrclinonc.2013.160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
76 Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009;23:449-56. [PMID: 19005483 DOI: 10.1038/leu.2008.325] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
77 Tessier C, Allard T, Boudreault JS, Kaedbey R, Éthier V, Fortin F, Pavic M. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Curr Oncol 2021;28:2029-39. [PMID: 34073289 DOI: 10.3390/curroncol28030188] [Reference Citation Analysis]
78 Lipe B, Kambhampati S, Veldhuizen PV, Yacoub A, Aljitawi O, Mikhael J. Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer J 2017;7:646. [PMID: 29238066 DOI: 10.1038/s41408-017-0015-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
79 González-Calle V, Dávila J, Escalante F, de Coca AG, Aguilera C, López R, Bárez A, Alonso JM, Hernández R, Hernández JM, de la Fuente P, Puig N, Ocio EM, Gutiérrez NC, García-Sanz R, Mateos MV. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia 2016;30:2026-31. [PMID: 27133826 DOI: 10.1038/leu.2016.123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
80 Fiala MA, Dukeman J, Tuchman SA, Keller M, Vij R, Wildes TM. Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. JCO Clin Cancer Inform 2017;1. [PMID: 30547156 DOI: 10.1200/CCI.17.00089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
81 Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, Madduri D, Mazumdar M, Parekh S, Chari A. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv 2018;2:1470-9. [PMID: 29945937 DOI: 10.1182/bloodadvances.2018016998] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
82 Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015;125:3049-58. [PMID: 25838343 DOI: 10.1182/blood-2014-11-568881] [Cited by in Crossref: 162] [Cited by in F6Publishing: 147] [Article Influence: 27.0] [Reference Citation Analysis]
83 Yu CY, Xiang S, Huang Z, Johnson TS, Zhan X, Han Z, Abu Zaid M, Huang K. Gene Co-expression Network and Copy Number Variation Analyses Identify Transcription Factors Associated With Multiple Myeloma Progression. Front Genet 2019;10:468. [PMID: 31156714 DOI: 10.3389/fgene.2019.00468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
84 Salem DA, Korde N, Venzon DJ, Liewehr DJ, Maric I, Calvo KR, Braylan R, Tembhare PR, Yuan CM, Landgren CO, Stetler-Stevenson M. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Leuk Lymphoma 2018;59:178-86. [PMID: 28540748 DOI: 10.1080/10428194.2017.1321746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
85 Maura F, Rustad EH, Boyle EM, Morgan GJ. Reconstructing the evolutionary history of multiple myeloma. Best Pract Res Clin Haematol 2020;33:101145. [PMID: 32139011 DOI: 10.1016/j.beha.2020.101145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
86 Fernando RC, Mazzotti DR, Azevedo H, Sandes AF, Rizzatti EG, de Oliveira MB, Alves VLF, Eugênio AIP, de Carvalho F, Dalboni MA, Martins DC, Colleoni GWB. Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism. Sci Rep 2019;9:1056. [PMID: 30705326 DOI: 10.1038/s41598-018-38314-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
87 Kunacheewa C, Manasanch EE. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Best Pract Res Clin Haematol 2020;33:101152. [PMID: 32139017 DOI: 10.1016/j.beha.2020.101152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
88 Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, Geraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O'Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P. Insights on Multiple Myeloma Treatment Strategies. Hemasphere 2019;3:e163. [PMID: 31723802 DOI: 10.1097/HS9.0000000000000163] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
89 Gao M, Yang G, Tompkins VS, Gao L, Wu X, Tao Y, Hu X, Hou J, Han Y, Xu H, Zhan F, Shi J. Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials. PLoS One 2014;9:e109758. [PMID: 25279718 DOI: 10.1371/journal.pone.0109758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
90 Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep 2020;12:9054. [PMID: 33408844 DOI: 10.4081/hr.2020.9054] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Bahuaud M, Bodilis H, Malphettes M, Maugard Landre A, Matondo C, Bouscary D, Batteux F, Launay O, Fermand JP. Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study. Heliyon 2017;3:e00441. [PMID: 29159320 DOI: 10.1016/j.heliyon.2017.e00441] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
92 Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013;122:4172-81. [PMID: 24144641 DOI: 10.1182/blood-2013-08-520890] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
93 Ullah A, Omar N, Savage NM, Bollag RJ, Singh G. Immune subtraction for improved resolution in serum protein immunofixation electrophoresis and antibody isotype determination in a patient with autoantibody. Pract Lab Med 2021;26:e00240. [PMID: 34124325 DOI: 10.1016/j.plabm.2021.e00240] [Reference Citation Analysis]
94 Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008;112:3122-5. [PMID: 18669874 DOI: 10.1182/blood-2008-06-164228] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 5.6] [Reference Citation Analysis]
95 Gjeorgjievski M, Purohit T, Amin MB, Kurtin PJ, Cappell MS. Upper Gastrointestinal Bleeding from Gastric Amyloidosis in a Patient with Smoldering Multiple Myeloma. Case Rep Gastrointest Med 2015;2015:320120. [PMID: 26366309 DOI: 10.1155/2015/320120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
96 Prideaux SM, Conway O'Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol 2014;2014:864058. [PMID: 24803933 DOI: 10.1155/2014/864058] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
97 Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK. Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J 2019;9:39. [PMID: 30914633 DOI: 10.1038/s41408-019-0199-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
98 Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA. 2008;105:1285-1290. [PMID: 18202175 DOI: 10.1073/pnas.0711293105] [Cited by in Crossref: 176] [Cited by in F6Publishing: 173] [Article Influence: 13.5] [Reference Citation Analysis]
99 Levine AJ, Jenkins NA, Copeland NG. The Roles of Initiating Truncal Mutations in Human Cancers: The Order of Mutations and Tumor Cell Type Matters. Cancer Cell 2019;35:10-5. [PMID: 30645969 DOI: 10.1016/j.ccell.2018.11.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 19.0] [Reference Citation Analysis]
100 Wennmann M, Kintzelé L, Piraud M, Menze BH, Hielscher T, Hofmanninger J, Wagner B, Kauczor HU, Merz M, Hillengass J, Langs G, Weber MA. Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget 2018;9:25254-64. [PMID: 29861868 DOI: 10.18632/oncotarget.25402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
101 Gonsalves WI, Jang JS, Jessen E, Hitosugi T, Evans LA, Jevremovic D, Pettersson XM, Bush AG, Gransee J, Anderson EI, Kumar SK, Nair KS. In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer Metab 2020;8:29. [PMID: 33308307 DOI: 10.1186/s40170-020-00235-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
102 Ferrarazzo G, Chiola S, Capitanio S, Donegani MI, Miceli A, Raffa S, Tagliafico AS, Morbelli S, Bauckneht M. Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting. Diagnostics (Basel) 2021;11:230. [PMID: 33546455 DOI: 10.3390/diagnostics11020230] [Reference Citation Analysis]
103 Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, Lacy MQ, Buadi FK, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa L, Kourelis TV, Kyle RA, Gertz MA, Kumar SK. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia 2017;31:130-5. [PMID: 27457702 DOI: 10.1038/leu.2016.205] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
104 Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 2017;17:543-56. [PMID: 28835722 DOI: 10.1038/nrc.2017.63] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 24.5] [Reference Citation Analysis]
105 Ahn IE, Mailankody S, Korde N, Landgren O. Dilemmas in treating smoldering multiple myeloma. J Clin Oncol 2015;33:115-23. [PMID: 25422486 DOI: 10.1200/JCO.2014.56.4351] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
106 Cooke RE, Gherardin NA, Harrison SJ, Quach H, Godfrey DI, Prince M, Koldej R, Ritchie DS. Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. J Transl Med 2016;14:259. [PMID: 27599546 DOI: 10.1186/s12967-016-0994-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
107 Keshavarz-Fathi M, Rezaei N. Cancer Immunoprevention: Current Status and Future Directions. Arch Immunol Ther Exp (Warsz) 2021;69:3. [PMID: 33638703 DOI: 10.1007/s00005-021-00604-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc 2016;91:101-19. [PMID: 26763514 DOI: 10.1016/j.mayocp.2015.11.007] [Cited by in Crossref: 234] [Cited by in F6Publishing: 211] [Article Influence: 46.8] [Reference Citation Analysis]
109 Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget 2016;7:6521-37. [PMID: 26695547 DOI: 10.18632/oncotarget.6658] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
110 Ho M, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia 2020;34:3111-25. [PMID: 33046818 DOI: 10.1038/s41375-020-01051-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
111 Baertsch MA, Goldschmidt H. [Multiple myeloma : What has been confirmed in therapy?]. Internist (Berl) 2017;58:1250-7. [PMID: 29098319 DOI: 10.1007/s00108-017-0337-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Tagliafico AS. Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging? World J Radiol 2021; 13(7): 223-226 [PMID: 34367508 DOI: 10.4329/wjr.v13.i7.223] [Reference Citation Analysis]
113 Sasseville VG, Mansfield KG, Mankowski JL, Tremblay C, Terio KA, Mätz-Rensing K, Gruber-Dujardin E, Delaney MA, Schmidt LD, Liu D, Markovits JE, Owston M, Harbison C, Shanmukhappa S, Miller AD, Kaliyaperumal S, Assaf BT, Kattenhorn L, Macri SC, Simmons HA, Baldessari A, Sharma P, Courtney C, Bradley A, Cline JM, Reindel JF, Hutto DL, Montali RJ, Lowenstine LJ. Meeting report: Spontaneous lesions and diseases in wild, captive-bred, and zoo-housed nonhuman primates and in nonhuman primate species used in drug safety studies. Vet Pathol 2012;49:1057-69. [PMID: 23135296 DOI: 10.1177/0300985812461655] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
114 Zhou Y, Nair B, Shaughnessy JD Jr, Cartron MA, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. Br J Haematol 2009;145:637-41. [PMID: 19344415 DOI: 10.1111/j.1365-2141.2009.07670.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
115 Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014;123:78-85. [PMID: 24144643 DOI: 10.1182/blood-2013-07-515239] [Cited by in Crossref: 123] [Cited by in F6Publishing: 112] [Article Influence: 15.4] [Reference Citation Analysis]
116 Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Melton LJ 3rd, Rajkumar SV. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012;119:4462-6. [PMID: 22451426 DOI: 10.1182/blood-2011-10-384768] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
117 Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010;85:945-8. [PMID: 20884827 DOI: 10.4065/mcp.2010.0520] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
118 Fulciniti M, Munshi NC, Martinez-Lopez J. Deep Response in Multiple Myeloma: A Critical Review. Biomed Res Int 2015;2015:832049. [PMID: 26783530 DOI: 10.1155/2015/832049] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
119 Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. Expert Rev Hematol 2014;7:21-31. [PMID: 24483346 DOI: 10.1586/17474086.2014.882224] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
120 Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RK, Stockley DM, Orchard KH, Cross NC, Harrison CJ, Ross FM; UK Myeloma Forum. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 2009;94:1708-13. [PMID: 19996118 DOI: 10.3324/haematol.2009.011064] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
121 Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res 2011;17:1243-52. [PMID: 21411440 DOI: 10.1158/1078-0432.CCR-10-1822] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
122 Al-Farsi K. Multiple myeloma: an update. Oman Med J 2013;28:3-11. [PMID: 23386937 DOI: 10.5001/omj.2013.02] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
123 Abramson HN. Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther 2021;10:343-71. [PMID: 34527606 DOI: 10.2147/ITT.S306103] [Reference Citation Analysis]
124 Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962-2972. [PMID: 18332230 DOI: 10.1182/blood-2007-10-078022] [Cited by in Crossref: 559] [Cited by in F6Publishing: 502] [Article Influence: 43.0] [Reference Citation Analysis]
125 Kristinsson SY, Landgren O, Rajkumar VS. Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. Cancer J 2009;15:473-8. [PMID: 20010166 DOI: 10.1097/PPO.0b013e3181c60f08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
126 Zhao JT, Jiang XY, Yang C, Chen M, Lan XL, Du JH, Zhou DB, Zhuang JL. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10]. Zhonghua Xue Ye Xue Za Zhi 2021;42:295-301. [PMID: 33979973 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.005] [Reference Citation Analysis]
127 Landgren O. Shall we treat smoldering multiple myeloma in the near future? Hematology Am Soc Hematol Educ Program 2017;2017:194-204. [PMID: 29222256 DOI: 10.1182/asheducation-2017.1.194] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
128 Jelinek T, Paiva B, Hajek R. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. Front Immunol 2018;9:2431. [PMID: 30505301 DOI: 10.3389/fimmu.2018.02431] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 18.0] [Reference Citation Analysis]
129 Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Melton LJ 3rd, Benson JT, Kumar S, Rajkumar SV. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol 2014;1:e28-36. [PMID: 25530988 DOI: 10.1016/S2352-3026(14)70001-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
130 Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43:676-681. [PMID: 28061985 DOI: 10.1053/j.seminoncol.2016.11.004] [Cited by in Crossref: 162] [Cited by in F6Publishing: 154] [Article Influence: 32.4] [Reference Citation Analysis]
131 Kim EB, Yee AJ, Raje N. Treatment of Smoldering Multiple Myeloma: Ready for Prime Time? Cancers (Basel) 2020;12:E1223. [PMID: 32414145 DOI: 10.3390/cancers12051223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
132 Ho M, Bianchi G, Anderson KC. Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Rev Precis Med Drug Dev 2020;5:67-85. [PMID: 34414281 DOI: 10.1080/23808993.2020.1732205] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
133 Korde N, Maric I. Myelomagenesis: capturing early microenvironment changes. Semin Hematol 2011;48:13-21. [PMID: 21232654 DOI: 10.1053/j.seminhematol.2010.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
134 Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res 2013;19:985-94. [PMID: 23224402 DOI: 10.1158/1078-0432.CCR-12-2922] [Cited by in Crossref: 57] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
135 Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol 2020;38:1126-37. [PMID: 31652094 DOI: 10.1200/JCO.19.01740] [Cited by in Crossref: 62] [Cited by in F6Publishing: 38] [Article Influence: 31.0] [Reference Citation Analysis]
136 Chiecchio L, Dagrada GP, Protheroe RK, Stockley DM, Smith AG, Orchard KH, Cross NC, Harrison CJ, Ross FM; UK Myeloma Forum. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica 2009;94:1024-8. [PMID: 19454499 DOI: 10.3324/haematol.2008.004440] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
137 Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol 2021;14:151. [PMID: 34556161 DOI: 10.1186/s13045-021-01162-7] [Reference Citation Analysis]
138 Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27:941-6. [PMID: 23183428 DOI: 10.1038/leu.2012.296] [Cited by in Crossref: 149] [Cited by in F6Publishing: 123] [Article Influence: 16.6] [Reference Citation Analysis]
139 Tete SM, Bijl M, Sahota SS, Bos NA. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol 2014;5:257. [PMID: 24917865 DOI: 10.3389/fimmu.2014.00257] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
140 Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, Go R, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 2016;6:e454. [PMID: 27471870 DOI: 10.1038/bcj.2016.65] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
141 Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011;8:479-91. [PMID: 21522124 DOI: 10.1038/nrclinonc.2011.63] [Cited by in Crossref: 189] [Cited by in F6Publishing: 171] [Article Influence: 18.9] [Reference Citation Analysis]
142 . Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol 2018;93:981-1114. [PMID: 30400719 DOI: 10.1002/ajh.25117] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 27.7] [Reference Citation Analysis]
143 Berbari HE, Kumar SK. Initial Therapeutic Approaches to Patients with Multiple Myeloma. Adv Ther 2021;38:3694-711. [PMID: 34145483 DOI: 10.1007/s12325-021-01824-5] [Reference Citation Analysis]
144 Takasu M, Kaichi Y, Tani C, Date S, Akiyama Y, Kuroda Y, Sakai A, Awai K. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) magnetic resonance imaging as a biomarker for symptomatic multiple myeloma. PLoS One 2015;10:e0116842. [PMID: 25706753 DOI: 10.1371/journal.pone.0116842] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
145 Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? Front Oncol 2020;10:189. [PMID: 32181154 DOI: 10.3389/fonc.2020.00189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
146 Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST. Oncolytic Viruses for Multiple Myeloma Therapy. Cancers (Basel) 2018;10:E198. [PMID: 29903988 DOI: 10.3390/cancers10060198] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
147 Rangel-Pozzo A, Yu PLI, LaL S, Asbaghi Y, Sisdelli L, Tammur P, Tamm A, Punab M, Klewes L, Louis S, Knecht H, Olujohungbe A, Mai S. Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma. Cancers (Basel) 2021;13:1969. [PMID: 33921898 DOI: 10.3390/cancers13081969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
148 Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009;84:114-22. [PMID: 19181644 DOI: 10.4065/84.2.114] [Cited by in Crossref: 177] [Cited by in F6Publishing: 159] [Article Influence: 14.8] [Reference Citation Analysis]
149 Di Noto G, Paolini L, Zendrini A, Radeghieri A, Caimi L, Ricotta D. C-src enriched serum microvesicles are generated in malignant plasma cell dyscrasia. PLoS One 2013;8:e70811. [PMID: 23940647 DOI: 10.1371/journal.pone.0070811] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
150 Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011;117:5573-81. [PMID: 21441462 DOI: 10.1182/blood-2011-01-270140] [Cited by in Crossref: 117] [Cited by in F6Publishing: 101] [Article Influence: 11.7] [Reference Citation Analysis]
151 Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, Dingli D, Kapoor P, Gonsalves W, Gertz MA, Rajkumar SV. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J 2015;5:e364. [PMID: 26495861 DOI: 10.1038/bcj.2015.87] [Cited by in Crossref: 61] [Cited by in F6Publishing: 42] [Article Influence: 10.2] [Reference Citation Analysis]
152 Go RS, Heien HC, Sangaralingham LR, Habermann EB, Shah ND. Monoclonal Gammopathy of Undetermined Significance: Follow-up Patterns in the United States and Concordance With Clinical Practice Guidelines. Mayo Clin Proc Innov Qual Outcomes 2017;1:161-9. [PMID: 30225412 DOI: 10.1016/j.mayocpiqo.2017.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
153 Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J 2020;10:94. [PMID: 32989217 DOI: 10.1038/s41408-020-00359-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 28.0] [Reference Citation Analysis]
154 Sessa M, Cavazzini F, Cavallari M, Rigolin GM, Cuneo A. A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. Genes (Basel) 2020;11:E1453. [PMID: 33287156 DOI: 10.3390/genes11121453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 2018;182:495-503. [PMID: 29808907 DOI: 10.1111/bjh.15384] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
156 D'Agostino M, Bertamini L, Oliva S, Boccadoro M, Gay F. Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. Cancers (Basel) 2019;11:E2015. [PMID: 31847174 DOI: 10.3390/cancers11122015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
157 Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A, Ronca R, Chiarini M, Imberti L, Marini M, Rossi G, Presta M, Paiva B, Roccaro AM. Circulating microRNAs and Their Role in Multiple Myeloma. Noncoding RNA 2019;5:E37. [PMID: 31052608 DOI: 10.3390/ncrna5020037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
158 Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J 2018;8:125. [PMID: 30538223 DOI: 10.1038/s41408-018-0163-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
159 Qiu Y, Jiang XY, Luo YP, Li J, Zhou DB, Cao XX. [A 55-year-old male with anemia and monoclonal gammopathy]. Zhonghua Xue Ye Xue Za Zhi 2019;40:783-5. [PMID: 31648486 DOI: 10.3760/cma.j.issn.0253-2727.2019.09.017] [Reference Citation Analysis]
160 Maatouk I, He S, Becker N, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Schellberg D, Herzog W, Hillengass J. Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study. BMJ Open 2018;8:e021376. [PMID: 30061438 DOI: 10.1136/bmjopen-2017-021376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
161 Lomas OC, Mouhieddine TH, Tahri S, Ghobrial IM. Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. Cancers (Basel). 2020;12. [PMID: 32545521 DOI: 10.3390/cancers12061554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
162 Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front Immunol 2020;11:762. [PMID: 32457743 DOI: 10.3389/fimmu.2020.00762] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
163 Jean-Baptiste M, Gries KS, Lenderking WR, Fastenau J. Symptom burden and health-related quality of life impacts of smoldering multiple myeloma: the patient perspective. J Patient Rep Outcomes 2020;4:95. [PMID: 33165677 DOI: 10.1186/s41687-020-00253-2] [Reference Citation Analysis]
164 Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K. Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging 2016;11:423-35. [PMID: 27143866 DOI: 10.2147/CIA.S89465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
165 Raje N, Yee AJ. How We Approach Smoldering Multiple Myeloma. J Clin Oncol 2020;38:1119-25. [PMID: 32004107 DOI: 10.1200/JCO.19.02834] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
166 Kumar SK. Timing of treatment of smoldering myeloma: delay until progression. Blood Adv 2018;2:3050-3. [PMID: 30425069 DOI: 10.1182/bloodadvances.2018021238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
167 Chatterjee G, Gujral S, Subramanian PG, Tembhare PR. Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian J Hematol Blood Transfus 2017;33:303-15. [PMID: 28824230 DOI: 10.1007/s12288-017-0822-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
168 Salem KZ, Ghobrial IM. The road to cure in multiple myeloma starts with smoldering disease. Expert Opin Orphan Drugs 2015;3. [PMID: 25995973 DOI: 10.1517/21678707.2015.1036740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
169 Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 2013;27:220-5. [PMID: 22902362 DOI: 10.1038/leu.2012.236] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
170 Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, Hatzimichael E, Vassou A, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsonis MC, Konstantopoulos K, Spyroupoulou-Vlachou M, Terpos E, Dimopoulos MA; Greek Myeloma Study Group. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia 2014;28:2075-9. [PMID: 24637336 DOI: 10.1038/leu.2014.110] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
171 Kyrtsonis MC, Maltezas D, Koulieris E, Tzenou T, Harding SJ. Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders. World J Hematol 2013; 2(2): 6-12 [DOI: 10.5315/wjh.v2.i2.6] [Reference Citation Analysis]
172 Mateos MV, González-Calle V. Timing of treatment of smoldering myeloma: early treatment. Blood Adv 2018;2:3045-9. [PMID: 30425068 DOI: 10.1182/bloodadvances.2018021220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
173 Soliman AM, Lin TS, Mahakkanukrauh P, Das S. Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma. Int J Mol Sci 2020;21:E7539. [PMID: 33066062 DOI: 10.3390/ijms21207539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
174 Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest 2020;130:1565-75. [PMID: 32149732 DOI: 10.1172/JCI129205] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
175 Bellone M, Brevi A, Huber S. Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. Microbiol Mol Biol Rev 2020;84:e00064-19. [PMID: 32132244 DOI: 10.1128/MMBR.00064-19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
176 Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, Rahmat M, Flaifel A, Ferland B, Su NK, Agius MP, Park J, Manier S, Bustoros M, Huynh D, Capelletti M, Berrios B, Liu CJ, He MX, Braggio E, Fonseca R, Maruvka Y, Guerriero JL, Goldman M, van Allen E, McCarroll SA, Azzi J, Getz G, Ghobrial IM. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 2020;1:493-506. [PMID: 33409501 DOI: 10.1038/s43018-020-0053-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 43.0] [Reference Citation Analysis]
177 Vasco-Mogorrón MA, Campillo JA, Periago A, Cabañas V, Berenguer M, García-Garay MC, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, Muro M, Minguela A. Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms. Int J Mol Sci 2021;22:3895. [PMID: 33918790 DOI: 10.3390/ijms22083895] [Reference Citation Analysis]
178 Madhira BR, Konala VM, Adapa S, Naramala S, Ravella PM, Parikh K, Gentile TC. Recent Advances in the Management of Smoldering Multiple Myeloma. World J Oncol 2020;11:45-54. [PMID: 32284772 DOI: 10.14740/wjon1245] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:719-34. [PMID: 27291302 DOI: 10.1002/ajh.24402] [Cited by in Crossref: 241] [Cited by in F6Publishing: 228] [Article Influence: 60.3] [Reference Citation Analysis]
180 Abramson HN. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci 2020;21:E5192. [PMID: 32707894 DOI: 10.3390/ijms21155192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
181 Parra M, Baptista MJ, Genescà E, Llinàs-Arias P, Esteller M. Genetics and epigenetics of leukemia and lymphoma: from knowledge to applications, meeting report of the Josep Carreras Leukaemia Research Institute. Hematol Oncol 2020;38:432-8. [PMID: 32073154 DOI: 10.1002/hon.2725] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Chrzan R, Jurczyszyn A, Urbanik A. Whole-Body Low-Dose Computed Tomography (WBLDCT) in Assessment of Patients with Multiple Myeloma - Pilot Study and Standard Imaging Protocol Suggestion. Pol J Radiol 2017;82:356-63. [PMID: 28740565 DOI: 10.12659/PJR.901742] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
183 Rögnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Óskarsson JÞ, Pétursdóttir Í, Sigurðardóttir GÁ, Viðarsson B, Önundarson PT, Agnarsson BA, Sigurðardóttir M, Þorsteinsdóttir I, Ólafsson Í, Þórðardóttir ÁR, Eyþórsson E, Jónsson Á, Björnsson AS, Gunnarsson GÞ, Pálsson R, Indriðason ÓS, Gíslason GK, Ólafsson A, Hákonardóttir GK, Brinkhuis M, Halldórsdóttir SL, Ásgeirsdóttir TL, Steingrímsdóttir H, Danielsen R, Dröfn Wessman I, Kampanis P, Hulcrantz M, Durie BGM, Harding S, Landgren O, Kristinsson SY. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J 2021;11:94. [PMID: 34001889 DOI: 10.1038/s41408-021-00480-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. Blood Cancer J 2020;10:19. [PMID: 32066732 DOI: 10.1038/s41408-020-0284-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
185 Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK. Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol 2016;91:473-5. [PMID: 26840395 DOI: 10.1002/ajh.24319] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
186 Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335-48. [PMID: 22495321 DOI: 10.1038/nrc3257] [Cited by in Crossref: 548] [Cited by in F6Publishing: 506] [Article Influence: 60.9] [Reference Citation Analysis]
187 Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013;27:1738-44. [PMID: 23515097 DOI: 10.1038/leu.2013.86] [Cited by in Crossref: 129] [Cited by in F6Publishing: 112] [Article Influence: 16.1] [Reference Citation Analysis]
188 Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113:5418-5422. [PMID: 19234139 DOI: 10.1182/blood-2008-12-195008] [Cited by in Crossref: 351] [Cited by in F6Publishing: 310] [Article Influence: 29.3] [Reference Citation Analysis]
189 Huang BH, Li J. [Advances in the diagnosis and treatment of multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2018;39:605-8. [PMID: 30122026 DOI: 10.3760/cma.j.issn.0253-2727.2018.07.018] [Reference Citation Analysis]
190 Dhakal B, Girnius S, Hari P. Recent advances in understanding multiple myeloma. F1000Res 2016;5:F1000 Faculty Rev-2053. [PMID: 27610224 DOI: 10.12688/f1000research.8777.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
191 Weiss BM, Kuehl WM. Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol 2010;3:165-74. [PMID: 20473362 DOI: 10.1586/ehm.10.13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
192 Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, Salem K, Tai YT, Anand S, Mouhieddine TH, Chavda SJ, Boehner C, Elagina L, Neuse CJ, Cha J, Rahmat M, Taylor-Weiner A, Van Allen E, Kumar S, Kastritis E, Leshchiner I, Morgan EA, Laubach J, Casneuf T, Richardson P, Munshi NC, Anderson KC, Trippa L, Aguet F, Stewart C, Dimopoulos MA, Yong K, Bergsagel PL, Manier S, Getz G, Ghobrial IM. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol 2020;38:2380-9. [PMID: 32442065 DOI: 10.1200/JCO.20.00437] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 27.0] [Reference Citation Analysis]
193 Dinarello CA. Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. Mayo Clin Proc 2009;84:105-7. [PMID: 19181642 DOI: 10.4065/84.2.105] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
194 Bianchi G, Ghobrial IM. Does my patient with a serum monoclonal spike have multiple myeloma? Hematol Oncol Clin North Am 2012;26:383-93, ix. [PMID: 22463833 DOI: 10.1016/j.hoc.2012.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
195 Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 2010;29:317-29. [PMID: 20422276 DOI: 10.1007/s10555-010-9229-0] [Cited by in Crossref: 196] [Cited by in F6Publishing: 181] [Article Influence: 17.8] [Reference Citation Analysis]
196 Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121-1127. [PMID: 20410922 DOI: 10.1038/leu.2010.60] [Cited by in Crossref: 452] [Cited by in F6Publishing: 362] [Article Influence: 41.1] [Reference Citation Analysis]
197 Gagnon MF, Cardinal H, Emond JP, Latour M, Lemieux B. The Evolution of Monoclonal Gammopathy of Undetermined Significance in Kidney Transplant Recipients. Transplant Direct 2019;5:e489. [PMID: 31723584 DOI: 10.1097/TXD.0000000000000937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Hong J, Lee JH. Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med 2016;31:820-34. [PMID: 27604794 DOI: 10.3904/kjim.2015.408] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
199 Siveen KS, Mustafa N, Li F, Kannaiyan R, Ahn KS, Kumar AP, Chng WJ, Sethi G. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget 2014;5:634-48. [PMID: 24504138 DOI: 10.18632/oncotarget.1596] [Cited by in Crossref: 111] [Cited by in F6Publishing: 106] [Article Influence: 18.5] [Reference Citation Analysis]
200 Seppänen M. Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies. Clin Exp Immunol 2014;178 Suppl 1:10-3. [PMID: 25546744 DOI: 10.1111/cei.12493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
201 Landgren O, Rajkumar SV. Development of early treatment strategies for high-risk myeloma precursor disease in the future. Semin Hematol 2011;48:66-72. [PMID: 21232660 DOI: 10.1053/j.seminhematol.2010.11.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
202 Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O. Host-related immunodeficiency in the development of multiple myeloma. Leuk Lymphoma 2018;59:1127-32. [PMID: 28792255 DOI: 10.1080/10428194.2017.1361026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
203 Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutiérrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014;28:384-90. [PMID: 23817176 DOI: 10.1038/leu.2013.199] [Cited by in Crossref: 173] [Cited by in F6Publishing: 168] [Article Influence: 21.6] [Reference Citation Analysis]
204 Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci 2016;1364:32-51. [PMID: 27002787 DOI: 10.1111/nyas.13038] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 11.4] [Reference Citation Analysis]
205 Epstein MM, Saphirak C, Zhou Y, LeBlanc C, Rosmarin AG, Ash A, Singh S, Fisher K, Birmann BM, Gurwitz JH. Identifying monoclonal gammopathy of undetermined significance in electronic health data. Pharmacoepidemiol Drug Saf 2020;29:69-76. [PMID: 31736189 DOI: 10.1002/pds.4912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Huang W, Qian T, Huang Z, Liu Y, Cui L, Zhu P, Zhong Q, Zeng T, Fu L, Si C, Deng C. Increased expression of IFI16 predicts adverse prognosis in multiple myeloma. Pharmacogenomics J 2021;21:520-32. [PMID: 33712724 DOI: 10.1038/s41397-021-00230-y] [Reference Citation Analysis]
207 Zhao AL, Shen KN, Wang JN, Huo LQ, Li J, Cao XX. Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies. Cancer Manag Res 2019;11:5599-611. [PMID: 31296995 DOI: 10.2147/CMAR.S205623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
208 Ghobrial IM, Landgren O. How I treat smoldering multiple myeloma. Blood 2014;124:3380-8. [PMID: 25298034 DOI: 10.1182/blood-2014-08-551549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
209 Wang T, Zhang Y, Li Q, Jia S, Shi C, Niu K, Liu B. Acute kidney injury in cancer patients and impedance cardiography-assisted renal replacement therapy: Experience from the onconephrology unit of a Chinese tertiary hospital. Exp Ther Med. 2017;14:5671-5677. [PMID: 29285109 DOI: 10.3892/etm.2017.5244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
210 Oben B, Froyen G, Maclachlan KH, Leongamornlert D, Abascal F, Zheng-Lin B, Yellapantula V, Derkach A, Geerdens E, Diamond BT, Arijs I, Maes B, Vanhees K, Hultcrantz M, Manasanch EE, Kazandjian D, Lesokhin A, Dogan A, Zhang Y, Mikulasova A, Walker B, Morgan G, Campbell PJ, Landgren O, Rummens JL, Bolli N, Maura F. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun 2021;12:1861. [PMID: 33767199 DOI: 10.1038/s41467-021-22140-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
211 Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood 2014;124:3043-51. [PMID: 25293776 DOI: 10.1182/blood-2014-07-552059] [Cited by in Crossref: 147] [Cited by in F6Publishing: 140] [Article Influence: 21.0] [Reference Citation Analysis]
212 Tan E, Weiss BM, Mena E, Korde N, Choyke PL, Landgren O. Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma 2011;52:1630-40. [PMID: 21649546 DOI: 10.3109/10428194.2011.573036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
213 Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J 2020;10:102. [PMID: 33067414 DOI: 10.1038/s41408-020-00366-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
214 Madan S, Kyle RA, Greipp PR. Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. Mayo Clin Proc 2010;85:300. [PMID: 20194156 DOI: 10.4065/mcp.2009.0653] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
215 Guedez L, Stetler-Stevenson WG. The prognostic value of TIMP-1 in multiple myeloma. Leuk Res 2010;34:576-7. [PMID: 19878997 DOI: 10.1016/j.leukres.2009.10.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
216 Bladé J, Dimopoulos M, Rosiñol L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010;28:690-7. [PMID: 20026810 DOI: 10.1200/JCO.2009.22.2257] [Cited by in Crossref: 80] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
217 Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Puig N, García-Mateo A, García-Sánchez O, Corral-Mateos A, Burgos L, Blanco E, Hernández-Martín J, Pontes R, Díez-Campelo M, Millacoy P, Rodríguez-Otero P, Prosper F, Merino J, Vidriales MB, García-Sanz R, Romero A, Palomera L, Ríos-Tamayo R, Pérez-Andrés M, Blanco JF, González M, van Dongen JJM, Durie B, Mateos MV, San-Miguel J, Orfao A; EuroFlow consortium. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 2018;8:117. [PMID: 30455467 DOI: 10.1038/s41408-018-0153-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
218 Isola I, Moreno DF, Moga E, Mena MP, Tovar N, Rodríguez-Lobato LG, Oliver-Caldés A, Salgado MC, Brasó-Maristany F, Yagüe J, Cibeira MT, Prat A, Rosiñol L, Bladé J, Fernández de Larrea C. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Ann Hematol 2021. [PMID: 34463804 DOI: 10.1007/s00277-021-04653-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 López-Corral L, Mateos MV, Corchete LA, Sarasquete ME, de la Rubia J, de Arriba F, Lahuerta JJ, García-Sanz R, San Miguel JF, Gutiérrez NC. Genomic analysis of high-risk smoldering multiple myeloma. Haematologica 2012;97:1439-43. [PMID: 22331267 DOI: 10.3324/haematol.2011.060780] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
220 Pozzi S, Raje N. The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist 2011;16:651-62. [PMID: 21493759 DOI: 10.1634/theoncologist.2010-0225] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]